Az adalimumab biológiai terápia hatékonysága és biztonságossága

Translated title of the contribution: The effectivity and safety of the biological therapy with adalimumab

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

The adalimumab is a human, recombinant antibody, which is able to give an effective therapy modality in patients with rheumatoid arthritis, polyarticular juvenil idiopathic arthritis, psoriasis, arthritis psoriatica, spondylitis ankylopoetica, as well as with Crohn-disease. The adalimumab has got a high affinity binding to tumor necrosis factor (TNF) -alfa, this way it inhibits the interactions with TNF and its receptors (soluble and membrane associated). It could be well tolerated and safe, it improves the the quality of life in patients. The possible side effects can be decreased by the careful observation and usual control of patients. The authors discuss in details the publications connected with adalimumab in the above mentioned diseases.

Translated title of the contributionThe effectivity and safety of the biological therapy with adalimumab
Original languageHungarian
Pages (from-to)1215-1222
Number of pages8
JournalOrvosi hetilap
Volume150
Issue number26
DOIs
Publication statusPublished - Jun 1 2009

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'The effectivity and safety of the biological therapy with adalimumab'. Together they form a unique fingerprint.

  • Cite this